NCCN COLORECTAL CANCER GUIDELINES

1.888.443.3311

Web Site Search

ABOUT US

TEST MENU

ORDERING

CAREERS

EVENTS

YOUR ACCOUNT

PATIENT HEALTH

	UPDATED! NCCN Colorectal Cancer Guidelines KRAS

The guidelines now recommend testing to be performed on primary and/or metastatic tumors, as the literature suggests KRAS mutations are similar in both specimen types. Learn more about KRAS Mutational Analysis

BRAF – If KRAS is non-mutated, BRAF is now added to the guideline as an option. Patients with a known V600E mutation are unlikely to respond to anti-EGFR therapy. Optional BRAF testing was also added to the rectal cancer guidelines. Learn more about BRAF testing

Patients harboring both KRAS and BRAF mutations are unlikely to respond to anti-EGFR therapies.
Learn more about KRAS & BRAF testing in Colorectal Cancer

Mismatch Repair (MMR) testing should be considered for all patients ≤ 50 years of age. MMR testing is suggested for 5FU therapy. MSI-H patients may have a good prognosis and do not benefit from 5FU therapy. Learn More about MSI Testing.

UPDATED! NCCN Colorectal Cancer Guidelines KRAS